Last quarter (Q4 2023), Cyclerion Therapeutics's total revenue was $―, a decrease of -100.00% from the same quarter last year. In Q4, Cyclerion Therapeutics's net income was $-1.69M. See Cyclerion Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	-	-	$ 297.00K	$ 3.94M	$ 2.30M	$ 4.51M
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	$ 1.63M	$ 3.94M	-	-
Operating Expense	$ 12.95M	$ 12.95M	$ -44.67M	$ 58.26M	$ 85.23M	$ 129.54M
Operating Income	$ -12.95M	$ -12.95M	$ -44.37M	$ -54.31M	$ -82.93M	$ -125.04M
Net Non Operating Interest Income Expense	$ 88.00K	-	-	-	$ 588.00K	$ 2.03M
Other Income Expense	$ -270.00K	$ -358.00K	$ -294.00K	$ -2.70M	$ 4.54M	-
Pretax Income	$ -12.59M	$ -12.59M	$ -44.08M	$ -51.61M	$ -77.80M	$ -123.01M
Tax Provision	$ -5.00K	$ -5.00K	$ -2.69M	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -5.26M	$ -5.26M	$ -44.08M	$ -51.61M	$ -77.80M	$ -123.01M
Basic EPS	$ 0.74	$ -4.50	$ -1.01	$ -26.40	$ -2.56	$ -4.49
Diluted EPS	$ 0.33	$ -4.50	$ -1.01	$ -26.40	$ -2.56	$ -4.49
Basic Average Shares	$ 9.39M	$ 2.34M	$ 43.47M	$ 1.96M	$ 30.40M	$ 27.38M
Diluted Average Shares	$ 9.39M	$ 2.34M	$ 43.47M	$ 1.96M	$ 30.40M	$ 27.38M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 12.95M	$ 12.95M	$ 46.00M	$ 58.26M	$ 85.23M	$ 129.54M
Net Income From Continuing And Discontinued Operation	$ -5.26M	$ -5.26M	$ -44.08M	$ -51.61M	$ -77.80M	$ -123.01M
Normalized Income	$ -786.31K	$ -9.86M	$ -48.10M	-	$ -82.35M	$ -123.01M
Interest Expense	-	-	-	-	-	-
EBIT	$ -12.59M	$ -12.59M	$ -44.08M	$ -51.61M	$ -82.93M	$ -125.04M
EBITDA	$ -12.59M	$ -12.59M	$ -44.01M	$ -51.14M	$ -80.64M	$ -122.34M

Currency in USD

Cyclerion Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing